Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 4:18 PM
Ignite Modification Date: 2025-12-24 @ 4:18 PM
NCT ID: NCT00768066
Eligibility Criteria: Inclusion Criteria: * Diagnosis of chronic ischemic left ventricular dysfunction secondary to MI. * Be a candidate for cardiac catheterization. * Been treated with appropriate maximal medical therapy for heart failure or post-infarction left ventricular dysfunction. * Ejection fraction less than or equal to 50%. * Able to perform a metabolic stress test. Exclusion Criteria: * Baseline glomerular filtration rate \< 45 ml/min/1.73m2. * Presence of a mechanical aortic valve or heart constrictive device. * Documented presence of aortic stenosis (aortic stenosis graded as ≥+2 equivalent to an orifice area of 1.5cm2 or less). * Documented presence of moderate to severe aortic insufficiency (echocardiographic assessment of aortic insufficiency graded as ≥+2). * Evidence of a life-threatening arrhythmia (nonsustained ventricular tachycardia ≥ 20 consecutive beats or complete heart block) or QTc interval \> 550 ms on screening ECG. In addition; patients with sustained or a short run of ventricular tachycardia on ECG or 48 hour Ambulatory ECG during the screening period will be removed from the protocol. * Documented unstable angina. * AICD firing in the past 60 days prior to the procedure. * Contra-indication to performance of a magnetic resonance imaging scan. * Be eligible for or require coronary artery revascularization. * Have a hematologic abnormality as evidenced by hematocrit \< 25%, white blood cell \< 2,500/ul or platelet values \< 100,000/ul without another explanation. * Have liver dysfunction, as evidenced by enzymes (ALT and AST) greater than three times the ULN. * Have a coagulopathy condition = (INR \> 1.3) not due to a reversible cause. * Known, serious radiographic contrast allergy. * Known allergies to penicillin or streptomycin. * Organ transplant recipient. * Clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma. * Non-cardiac condition that limits lifespan to \< 1 year. * On chronic therapy with immunosuppressant medication. * Serum positive for HIV, hepatitis BsAg, or non-viremic hepatitis C. * Female patient who is pregnant, nursing, or of child-bearing potential and not using effective birth control.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 21 Years
Maximum Age: 90 Years
Study: NCT00768066
Study Brief:
Protocol Section: NCT00768066